Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) Inhibitors

Inclusion Criteria: * Diagnosis of Rheumatoid Arthritis (RA) * Moderate to severe disease activity of RA * The patient receives Tumor Necrosis Factor (TNF) inhibitor in combination with at least 1 synthetic Disease Modifying Antirheumatic Drug (DMARD) * The decision to prescribe a TNF inhibitor in combination with DMARD is made by the treating physician, prior to and independently from the decision to include the patient in this Non-Interventional Study (NIS) * Male or female patients ≥ 18 years of age, considered by the treating physician to be reliable and capable of adhering to the observational plan (eg, able to understand and complete questionnaires) * The patient personally signed and dated Patient Data Consent Form (PDCF) prior to Visit 2 * Treatment is according to the Summary of Product Characteristics (SmPC) Exclusion Criteria: * Known contraindications to Tumor Necrosis Factor (TNF) inhibitors * Prior use of any TNF inhibitors (including Adalimumab, Etanercept, Infliximab, Certolizumab, or Golimumab), or other biologic DMARDs (including Abatacept, Rituximab, Tocilizumab, or Anakinra) * Participation in an investigational study